As of 2025-07-12, the Intrinsic Value of MEI Pharma Inc (MEIP) is 28.02 USD. This MEIP valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 2.69 USD, the upside of MEI Pharma Inc is 941.80%.
The range of the Intrinsic Value is 24.30 - 33.55 USD
Based on its market price of 2.69 USD and our intrinsic valuation, MEI Pharma Inc (MEIP) is undervalued by 941.80%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 24.30 - 33.55 | 28.02 | 941.8% |
| DCF (Growth 10y) | 28.30 - 38.65 | 32.49 | 1107.8% |
| DCF (EBITDA 5y) | 34.33 - 39.30 | 37.57 | 1296.8% |
| DCF (EBITDA 10y) | 36.33 - 43.25 | 40.34 | 1399.5% |
| Fair Value | -23.77 - -23.77 | -23.77 | -983.68% |
| P/E | (64.66) - 65.69 | (17.93) | -766.7% |
| EV/EBITDA | (36.77) - 80.36 | 5.41 | 101.2% |
| EPV | (35.50) - (45.44) | (40.47) | -1604.4% |
| DDM - Stable | (25.82) - (50.56) | (38.19) | -1519.7% |
| DDM - Multi | 13.45 - 21.30 | 16.55 | 515.2% |
| Market Cap (mil) | 17.92 |
| Beta | 0.52 |
| Outstanding shares (mil) | 6.66 |
| Enterprise Value (mil) | -2.56 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.18% |
| Cost of Debt | 5.00% |
| WACC | 7.42% |